tiprankstipranks
Avalo Therapeutics, Inc. (AVTX)
NASDAQ:AVTX
US Market
AVTX
Avalo Therapeutics
RESEARCH TOOLSreports
Want to see AVTX full AI Analyst Report?

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

1,072 Followers
See the Price Targets and Ratings of:

AVTX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Avalo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$47.11
▲(226.48% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $47.11 with a high forecast of $60.00 and a low forecast of $34.00. The average price target represents a 226.48% change from the last price of $14.43.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","32":"$32","61":"$61","17.5":"$17.5","46.5":"$46.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.111111111111114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,17.5,32,46.5,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.71,17.270769230769233,20.831538461538464,24.392307692307693,27.953076923076924,31.513846153846156,35.074615384615385,38.635384615384616,42.19615384615385,45.75692307692308,49.31769230769231,52.87846153846154,56.43923076923077,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.71,16.27931623931624,18.84863247863248,21.41794871794872,23.98726495726496,26.5565811965812,29.125897435897436,31.695213675213676,34.264529914529916,36.83384615384615,39.4031623931624,41.972478632478634,44.54179487179488,{"y":47.111111111111114,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.71,15.27076923076923,16.83153846153846,18.392307692307693,19.953076923076924,21.513846153846153,23.074615384615385,24.635384615384616,26.196153846153848,27.756923076923076,29.317692307692308,30.87846153846154,32.43923076923077,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$47.11Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on AVTX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$36→$39
Buy
170.27%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on AVTX
Jason Butler
Citizens JMP
Citizens JMP
$62→$55
Buy
281.15%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
H.C. Wainwright Analyst forecast on AVTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$40→$35
Buy
142.55%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $35 from $40 at H.C. WainwrightAvalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
Mizuho Securities Analyst forecast on AVTX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$39→$45
Buy
211.85%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
Wedbush Analyst forecast on AVTX
Robert Driscoll
Wedbush
Wedbush
$40→$34
Buy
135.62%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
BTIG Analyst forecast on AVTX
Julian Harrison
BTIG
BTIG
$58
Buy
301.94%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), NeuroPace (NASDAQ: NPCE) and Avalo Therapeutics (NASDAQ: AVTX)
Piper Sandler Analyst forecast on AVTX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$48→$60
Buy
315.80%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Guggenheim Analyst forecast on AVTX
Yatin Suneja
Guggenheim
Guggenheim
$50
Buy
246.50%
Upside
Reiterated
05/06/26
Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Wolfe Research Analyst forecast on AVTX
Andy Chen
Wolfe Research
Wolfe Research
$48
Buy
232.64%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
TD Cowen Analyst forecast on AVTX
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Reiterated
10/14/25
Oppenheimer Analyst forecast on AVTX
Leland Gershell
Oppenheimer
Oppenheimer
$35
Buy
142.55%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on AVTX
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$53.57→$19.8
Buy
37.19%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on AVTX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$36→$39
Buy
170.27%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on AVTX
Jason Butler
Citizens JMP
Citizens JMP
$62→$55
Buy
281.15%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
H.C. Wainwright Analyst forecast on AVTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$40→$35
Buy
142.55%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $35 from $40 at H.C. WainwrightAvalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
Mizuho Securities Analyst forecast on AVTX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$39→$45
Buy
211.85%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
Wedbush Analyst forecast on AVTX
Robert Driscoll
Wedbush
Wedbush
$40→$34
Buy
135.62%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
BTIG Analyst forecast on AVTX
Julian Harrison
BTIG
BTIG
$58
Buy
301.94%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), NeuroPace (NASDAQ: NPCE) and Avalo Therapeutics (NASDAQ: AVTX)
Piper Sandler Analyst forecast on AVTX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$48→$60
Buy
315.80%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Guggenheim Analyst forecast on AVTX
Yatin Suneja
Guggenheim
Guggenheim
$50
Buy
246.50%
Upside
Reiterated
05/06/26
Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Wolfe Research Analyst forecast on AVTX
Andy Chen
Wolfe Research
Wolfe Research
$48
Buy
232.64%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
TD Cowen Analyst forecast on AVTX
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Reiterated
10/14/25
Oppenheimer Analyst forecast on AVTX
Leland Gershell
Oppenheimer
Oppenheimer
$35
Buy
142.55%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on AVTX
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$53.57→$19.8
Buy
37.19%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

3 Months
Julian HarrisonBTIG
Success Rate
5/8 ratings generated profit
63%
Average Return
+26.27%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +26.27% per trade.
1 Year
Julian HarrisonBTIG
Success Rate
7/8 ratings generated profit
88%
Average Return
+75.59%
Copying Julian Harrison's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +75.59% per trade.
2 Years
Julian HarrisonBTIG
Success Rate
7/8 ratings generated profit
88%
Average Return
+80.97%
Copying Julian Harrison's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +80.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
5
11
12
21
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
5
11
12
21
In the current month, AVTX has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 47.11.
Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Next quarter’s earnings estimate for AVTX is -$0.62 with a range of -$0.98 to -$0.39. The previous quarter’s EPS was -$0.98. AVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for AVTX is -$0.62 with a range of -$0.98 to -$0.39. The previous quarter’s EPS was -$0.98. AVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.

AVTX Sales Forecast

Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.
Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics, Inc.’s 12-month average price target is 47.11.
    What is AVTX’s upside potential, based on the analysts’ average price target?
    Avalo Therapeutics, Inc. has 226.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVTX a Buy, Sell or Hold?
          Avalo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avalo Therapeutics, Inc.’s price target?
            The average price target for Avalo Therapeutics, Inc. is 47.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $34.00. The average price target represents 226.48% Increase from the current price of $14.43.
              What do analysts say about Avalo Therapeutics, Inc.?
              Avalo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of AVTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.